Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    MK-8931
Show Display Options
Rank Status Study
1 Not yet recruiting An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
Conditions: Amnestic Mild Cognitive Impairment;   Alzheimer's Disease;   Prodromal Alzheimer's Disease
Intervention: Drug: MK-8931
2 Completed A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])
Condition: Alzheimer's Disease
Interventions: Drug: MK-8931;   Drug: Placebo
3 Completed A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])
Condition: Alzheimer's Disease
Intervention: Drug: MK-8931
4 Active, not recruiting An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
Condition: Alzheimer's Disease
Interventions: Drug: Verubecestat (Part I and Part II);   Drug: Placebo (Part I);   Drug: Verubecestat (Part II)
5 Recruiting Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
Conditions: Amnestic Mild Cognitive Impairment;   Alzheimer's Disease;   Prodromal Alzheimer's Disease
Interventions: Drug: Verubecestat (Part I and Part II);   Drug: Placebo (Part I);   Drug: Verubecestat (Part II)

Indicates status has not been verified in more than two years